首页 > 最新文献

Frontiers of Medicine最新文献

英文 中文
Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis. TRMT2B基因变异与幼年肌萎缩侧索硬化症的相关性。
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2023-10-24 DOI: 10.1007/s11684-023-1005-y
Yanling Liu, Xi He, Yanchun Yuan, Bin Li, Zhen Liu, Wanzhen Li, Kaixuan Li, Shuo Tan, Quan Zhu, Zhengyan Tang, Feng Han, Ziqiang Wu, Lu Shen, Hong Jiang, Beisha Tang, Jian Qiu, Zhengmao Hu, Junling Wang

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons, and it demonstrates high clinical heterogeneity and complex genetic architecture. A variation within TRMT2B (c.1356G>T; p.K452N) was identified to be associated with ALS in a family comprising two patients with juvenile ALS (JALS). Two missense variations and one splicing variation were identified in 10 patients with ALS in a cohort with 910 patients with ALS, and three more variants were identified in a public ALS database including 3317 patients with ALS. A decreased number of mitochondria, swollen mitochondria, lower expression of ND1, decreased mitochondrial complex I activities, lower mitochondrial aerobic respiration, and a high level of ROS were observed functionally in patient-originated lymphoblastoid cell lines and TRMT2B interfering HEK293 cells. Further, TRMT2B variations overexpression cells also displayed decreased ND1. In conclusion, a novel JALS-associated gene called TRMT2B was identified, thus broadening the clinical and genetic spectrum of ALS.

肌萎缩侧索硬化症(ALS)是一种以运动神经元进行性变性为特征的致命性神经退行性疾病,具有高度的临床异质性和复杂的遗传结构。在一个由两名青少年ALS(JALS)患者组成的家族中,TRMT2B内的一种变异(c.1356G>T;p.K452N)被确定与ALS相关。在910名ALS患者的队列中,在10名ALS病人中发现了两种错义变异和一种剪接变异,在公共ALS数据库中又发现了三种变异,其中包括3317名ALS。在患者来源的淋巴母细胞样细胞系和TRMT2B干扰HEK293细胞中,观察到线粒体数量减少、线粒体肿胀、ND1表达降低、线粒体复合体I活性降低、线粒体有氧呼吸降低和ROS高水平。此外,TRMT2B变异过表达细胞也显示出ND1降低。总之,发现了一种名为TRMT2B的新型JALS相关基因,从而拓宽了ALS的临床和遗传谱。
{"title":"Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis.","authors":"Yanling Liu, Xi He, Yanchun Yuan, Bin Li, Zhen Liu, Wanzhen Li, Kaixuan Li, Shuo Tan, Quan Zhu, Zhengyan Tang, Feng Han, Ziqiang Wu, Lu Shen, Hong Jiang, Beisha Tang, Jian Qiu, Zhengmao Hu, Junling Wang","doi":"10.1007/s11684-023-1005-y","DOIUrl":"10.1007/s11684-023-1005-y","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons, and it demonstrates high clinical heterogeneity and complex genetic architecture. A variation within TRMT2B (c.1356G>T; p.K452N) was identified to be associated with ALS in a family comprising two patients with juvenile ALS (JALS). Two missense variations and one splicing variation were identified in 10 patients with ALS in a cohort with 910 patients with ALS, and three more variants were identified in a public ALS database including 3317 patients with ALS. A decreased number of mitochondria, swollen mitochondria, lower expression of ND1, decreased mitochondrial complex I activities, lower mitochondrial aerobic respiration, and a high level of ROS were observed functionally in patient-originated lymphoblastoid cell lines and TRMT2B interfering HEK293 cells. Further, TRMT2B variations overexpression cells also displayed decreased ND1. In conclusion, a novel JALS-associated gene called TRMT2B was identified, thus broadening the clinical and genetic spectrum of ALS.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects and mechanisms of acupuncture on women related health. 针灸对妇女健康的影响和机制。
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2023-12-27 DOI: 10.1007/s11684-023-1051-5
Huichao Qin, Jiaxing Feng, Xiaoke Wu

Globally, public health interventions have resulted in a 30-year increase in women's life expectancy. However, women's health has not increased when socioeconomic status is ignored. Women's health has become a major public health concern, for those women from developing countries are still struggling with infectious and labor-related diseases, and their counterparts in developed countries are suffering from physical and psychological disorders. In recent years, complementary and alternative medicine has attracted wide attentions with regards to maintaining women's health. Acupuncture, a crucial component of traditional Chinese medicine, has been used to treat many obstetric and gynecological diseases for thousands of years due to its analgesic and anti-inflammatory effects and its effects on stimulating the sympathetic/parasympathetic nervous system. To fully understand the mechanism through which acupuncture exerts its effects in these diseases would significantly extend the list of available interventions and would allow for more reasonable advice to be given to general practitioners. Therefore, by searching PubMed and CNKI regarding the use of acupuncture in treating obstetric and gynecological diseases, we aimed to summarize the proven evidence of using acupuncture in maintaining women's health by considering both its effectiveness and the underlying mechanisms behind its effects.

在全球范围内,公共卫生干预措施已使妇女的预期寿命延长了 30 年。然而,如果忽略社会经济地位,妇女的健康水平并没有提高。发展中国家的妇女仍在与传染病和与劳动有关的疾病作斗争,而发达国家的妇女则饱受生理和心理疾病的折磨,因此,妇女健康已成为公共卫生的一个主要问题。近年来,补充和替代医学在维护妇女健康方面受到广泛关注。针灸作为传统中医的重要组成部分,因其镇痛、消炎和刺激交感/副交感神经系统的作用,几千年来一直被用于治疗多种妇产科疾病。如果能充分了解针灸对这些疾病的作用机制,就能大大扩展现有的干预措施,并为全科医生提供更合理的建议。因此,我们通过检索PubMed和CNKI中有关针灸治疗妇产科疾病的内容,从针灸的疗效和作用机制两方面总结了针灸用于维护妇女健康的确凿证据。
{"title":"Effects and mechanisms of acupuncture on women related health.","authors":"Huichao Qin, Jiaxing Feng, Xiaoke Wu","doi":"10.1007/s11684-023-1051-5","DOIUrl":"10.1007/s11684-023-1051-5","url":null,"abstract":"<p><p>Globally, public health interventions have resulted in a 30-year increase in women's life expectancy. However, women's health has not increased when socioeconomic status is ignored. Women's health has become a major public health concern, for those women from developing countries are still struggling with infectious and labor-related diseases, and their counterparts in developed countries are suffering from physical and psychological disorders. In recent years, complementary and alternative medicine has attracted wide attentions with regards to maintaining women's health. Acupuncture, a crucial component of traditional Chinese medicine, has been used to treat many obstetric and gynecological diseases for thousands of years due to its analgesic and anti-inflammatory effects and its effects on stimulating the sympathetic/parasympathetic nervous system. To fully understand the mechanism through which acupuncture exerts its effects in these diseases would significantly extend the list of available interventions and would allow for more reasonable advice to be given to general practitioners. Therefore, by searching PubMed and CNKI regarding the use of acupuncture in treating obstetric and gynecological diseases, we aimed to summarize the proven evidence of using acupuncture in maintaining women's health by considering both its effectiveness and the underlying mechanisms behind its effects.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma 多组学联合分析揭示腹膜后脂肪肉瘤的代谢特征
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1020-z
Fu’an Xie, Yujia Niu, Lanlan Lian, Yue Wang, Aobo Zhuang, Guangting Yan, Yantao Ren, Xiaobing Chen, Mengmeng Xiao, Xi Li, Zhe Xi, Gen Zhang, Dongmei Qin, Kunrong Yang, Zhigang Zheng, Quan Zhang, Xiaogang Xia, Peng Li, Lingwei Gu, Ting Wu, Chenghua Luo, Shu-Hai Lin, Wengang Li

Retroperitoneal liposarcoma (RLPS) is the main subtype of retroperitoneal soft sarcoma (RSTS) and has a poor prognosis and few treatment options, except for surgery. The proteomic and metabolic profiles of RLPS have remained unclear. The aim of our study was to reveal the metabolic profile of RLPS. Here, we performed proteomic analysis (n = 10), metabolomic analysis (n = 51), and lipidomic analysis (n = 50) of retroperitoneal dedifferentiated liposarcoma (RDDLPS) and retroperitoneal well-differentiated liposarcoma (RWDLPS) tissue and paired adjacent adipose tissue obtained during surgery. Data analysis mainly revealed that glycolysis, purine metabolism, pyrimidine metabolism and phospholipid formation were upregulated in both RDDLPS and RWDLPS tissue compared with the adjacent adipose tissue, whereas the tricarboxylic acid (TCA) cycle, lipid absorption and synthesis, fatty acid degradation and biosynthesis, as well as glycine, serine, and threonine metabolism were downregulated. Of particular importance, the glycolytic inhibitor 2-deoxy-D-glucose and pentose phosphate pathway (PPP) inhibitor RRX-001 significantly promoted the antitumor effects of the MDM2 inhibitor RG7112 and CDK4 inhibitor abemaciclib. Our study not only describes the metabolic profiles of RDDLPS and RWDLPS, but also offers potential therapeutic targets and strategies for RLPS.

腹膜后脂肪肉瘤(RLPS)是腹膜后软肉瘤(RSTS)的主要亚型,预后较差,除手术治疗外,几乎没有其他治疗方法。RLPS的蛋白质组学和代谢谱仍不清楚。我们的研究旨在揭示RLPS的代谢特征。在此,我们对手术中获得的腹膜后低分化脂肪肉瘤(RDDLPS)和腹膜后高分化脂肪肉瘤(RWDLPS)组织以及配对的邻近脂肪组织进行了蛋白质组分析(10 例)、代谢组分析(51 例)和脂质组分析(50 例)。数据分析主要显示,与邻近脂肪组织相比,RDDLPS 和 RWDLPS 组织的糖酵解、嘌呤代谢、嘧啶代谢和磷脂形成均上调,而三羧酸(TCA)循环、脂质吸收和合成、脂肪酸降解和生物合成以及甘氨酸、丝氨酸和苏氨酸代谢均下调。尤其重要的是,糖酵解抑制剂2-脱氧-D-葡萄糖和磷酸戊糖途径(PPP)抑制剂RRX-001显著促进了MDM2抑制剂RG7112和CDK4抑制剂abemaciclib的抗肿瘤作用。我们的研究不仅描述了RDDLPS和RWDLPS的代谢特征,还为RLPS提供了潜在的治疗靶点和策略。
{"title":"Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma","authors":"Fu’an Xie, Yujia Niu, Lanlan Lian, Yue Wang, Aobo Zhuang, Guangting Yan, Yantao Ren, Xiaobing Chen, Mengmeng Xiao, Xi Li, Zhe Xi, Gen Zhang, Dongmei Qin, Kunrong Yang, Zhigang Zheng, Quan Zhang, Xiaogang Xia, Peng Li, Lingwei Gu, Ting Wu, Chenghua Luo, Shu-Hai Lin, Wengang Li","doi":"10.1007/s11684-023-1020-z","DOIUrl":"https://doi.org/10.1007/s11684-023-1020-z","url":null,"abstract":"<p>Retroperitoneal liposarcoma (RLPS) is the main subtype of retroperitoneal soft sarcoma (RSTS) and has a poor prognosis and few treatment options, except for surgery. The proteomic and metabolic profiles of RLPS have remained unclear. The aim of our study was to reveal the metabolic profile of RLPS. Here, we performed proteomic analysis (<i>n</i> = 10), metabolomic analysis (<i>n</i> = 51), and lipidomic analysis (<i>n</i> = 50) of retroperitoneal dedifferentiated liposarcoma (RDDLPS) and retroperitoneal well-differentiated liposarcoma (RWDLPS) tissue and paired adjacent adipose tissue obtained during surgery. Data analysis mainly revealed that glycolysis, purine metabolism, pyrimidine metabolism and phospholipid formation were upregulated in both RDDLPS and RWDLPS tissue compared with the adjacent adipose tissue, whereas the tricarboxylic acid (TCA) cycle, lipid absorption and synthesis, fatty acid degradation and biosynthesis, as well as glycine, serine, and threonine metabolism were downregulated. Of particular importance, the glycolytic inhibitor 2-deoxy-D-glucose and pentose phosphate pathway (PPP) inhibitor RRX-001 significantly promoted the antitumor effects of the MDM2 inhibitor RG7112 and CDK4 inhibitor abemaciclib. Our study not only describes the metabolic profiles of RDDLPS and RWDLPS, but also offers potential therapeutic targets and strategies for RLPS.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China COVID-19 的病原体演变、预防/控制策略和临床特征:中国的经验
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1043-5

Abstract

Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) was reported at the end of 2019 as a worldwide health concern causing a pandemic of unusual viral pneumonia and many other organ damages, which was defined by the World Health Organization as coronavirus disease 2019 (COVID-19). The pandemic is considered a significant threat to global public health till now. In this review, we have summarized the lessons learnt during the emergence and spread of SARS-CoV-2, including its prototype and variants. The overall clinical features of variants of concern (VOC), heterogeneity in the clinical manifestations, radiology and pathology of COVID-19 patients are also discussed, along with advances in therapeutic agents.

摘要 严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)于 2019 年年底被报道为一种世界性的健康问题,导致了非典型病毒性肺炎和许多其他器官损伤的大流行,世界卫生组织将其定义为 2019 年冠状病毒病(COVID-19)。迄今为止,该流行病被认为是对全球公共卫生的重大威胁。在本综述中,我们总结了 SARS-CoV-2 出现和传播过程中的经验教训,包括其原型和变种。我们还讨论了相关变种(VOC)的总体临床特征、COVID-19 患者临床表现的异质性、放射学和病理学,以及治疗药物的进展。
{"title":"Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China","authors":"","doi":"10.1007/s11684-023-1043-5","DOIUrl":"https://doi.org/10.1007/s11684-023-1043-5","url":null,"abstract":"<h3>Abstract</h3> <p>Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) was reported at the end of 2019 as a worldwide health concern causing a pandemic of unusual viral pneumonia and many other organ damages, which was defined by the World Health Organization as coronavirus disease 2019 (COVID-19). The pandemic is considered a significant threat to global public health till now. In this review, we have summarized the lessons learnt during the emergence and spread of SARS-CoV-2, including its prototype and variants. The overall clinical features of variants of concern (VOC), heterogeneity in the clinical manifestations, radiology and pathology of COVID-19 patients are also discussed, along with advances in therapeutic agents.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19 中药预防和治疗COVID-19的实践与原理
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1040-8
Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, Xiaolin Tong

Traditional Chinese medicine (TCM) has played an important role in the prevention and treatment of Coronavirus disease 2019 (COVID-19) epidemic in China. The integration of Chinese and Western medicine is an important feature of Chinese COVID-19 prevention and treatment. According to a series of evidence-based studies, TCM can reduce the infection rate of severe acute respiratory syndrome coronavirus 2 in high-risk groups. For patients with mild and moderate forms of COVID-19, TCM can relieve the related signs and symptoms, shorten the period of nucleic-acid negative conversion, and reduce conversion rate to the severe form of the disease. For COVID-19 patients with severe and critical illnesses, TCM can improve inflammatory indicators and blood oxygen saturation, shorten the hospital stay, and reduce the mortality rate. During recovery, TCM can improve patients’ symptoms, promote organ function recovery, boost the quality of patients’ life, and reduce the nucleic-acid repositive conversion rate. A series of mechanism research studies revealed that capability of TCM to treat COVID-19 through antiviral and anti-inflammatory effects, immune regulation, and protection of organ function via a multicomponent, multitarget, and multipathway approach.

中医药在中国冠状病毒病 2019(COVID-19)疫情防治中发挥了重要作用。中西医结合是中国 COVID-19 防治的重要特色。根据一系列循证研究,中医药可降低高危人群严重急性呼吸综合征冠状病毒2型的感染率。对于轻、中度COVID-19患者,中医药可以缓解相关症状和体征,缩短核酸阴转期,降低向重症的转化率。对于 COVID-19 重症和危重症患者,中医药可以改善炎症指标和血氧饱和度,缩短住院时间,降低死亡率。在康复期,中医药可以改善患者症状,促进器官功能恢复,提高患者生活质量,降低核酸重复转化率。一系列机理研究表明,中药可通过多成分、多靶点、多途径的抗病毒、抗炎、免疫调节和保护器官功能等作用治疗 COVID-19。
{"title":"Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19","authors":"Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, Xiaolin Tong","doi":"10.1007/s11684-023-1040-8","DOIUrl":"https://doi.org/10.1007/s11684-023-1040-8","url":null,"abstract":"<p>Traditional Chinese medicine (TCM) has played an important role in the prevention and treatment of Coronavirus disease 2019 (COVID-19) epidemic in China. The integration of Chinese and Western medicine is an important feature of Chinese COVID-19 prevention and treatment. According to a series of evidence-based studies, TCM can reduce the infection rate of severe acute respiratory syndrome coronavirus 2 in high-risk groups. For patients with mild and moderate forms of COVID-19, TCM can relieve the related signs and symptoms, shorten the period of nucleic-acid negative conversion, and reduce conversion rate to the severe form of the disease. For COVID-19 patients with severe and critical illnesses, TCM can improve inflammatory indicators and blood oxygen saturation, shorten the hospital stay, and reduce the mortality rate. During recovery, TCM can improve patients’ symptoms, promote organ function recovery, boost the quality of patients’ life, and reduce the nucleic-acid repositive conversion rate. A series of mechanism research studies revealed that capability of TCM to treat COVID-19 through antiviral and anti-inflammatory effects, immune regulation, and protection of organ function via a multicomponent, multitarget, and multipathway approach.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytokine storm and translating IL-6 biology into effective treatments for COVID-19 细胞因子风暴和将 IL-6 生物学转化为 COVID-19 的有效疗法
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1044-4
Tiantian Li, Dongsheng Wang, Haiming Wei, Xiaoling Xu

As of May 3, 2023, the Coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 760 million confirmed cases and over 6.9 million deaths. Several patients have developed pneumonia, which can deteriorate into acute respiratory distress syndrome. The primary etiology may be attributed to cytokine storm, which is triggered by the excessive release of proinflammatory cytokines and subsequently leads to immune dysregulation. Considering that high levels of interleukin-6 (IL-6) have been detected in several highly pathogenic coronavirus-infected diseases, such as severe acute respiratory syndrome in 2002, the Middle East respiratory syndrome in 2012, and COVID-19, the IL-6 pathway has emerged as a key in the pathogenesis of this hyperinflammatory state. Thus, we review the history of cytokine storm and the process of targeting IL-6 signaling to elucidate the pivotal role played by tocilizumab in combating COVID-19.

截至 2023 年 5 月 3 日,2019 年冠状病毒病(COVID-19)大流行已导致超过 7.6 亿例确诊病例和超过 690 万人死亡。一些患者出现肺炎,并可能恶化为急性呼吸窘迫综合征。主要病因可能是细胞因子风暴,它由促炎细胞因子的过度释放引发,随后导致免疫失调。考虑到在几种高致病性冠状病毒感染疾病(如 2002 年的严重急性呼吸系统综合征、2012 年的中东呼吸系统综合征和 COVID-19)中检测到高水平的白细胞介素-6(IL-6),IL-6 途径已成为这种高炎症状态发病机制的关键。因此,我们回顾了细胞因子风暴的历史和靶向 IL-6 信号传导的过程,以阐明托西珠单抗在抗击 COVID-19 中发挥的关键作用。
{"title":"Cytokine storm and translating IL-6 biology into effective treatments for COVID-19","authors":"Tiantian Li, Dongsheng Wang, Haiming Wei, Xiaoling Xu","doi":"10.1007/s11684-023-1044-4","DOIUrl":"https://doi.org/10.1007/s11684-023-1044-4","url":null,"abstract":"<p>As of May 3, 2023, the Coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 760 million confirmed cases and over 6.9 million deaths. Several patients have developed pneumonia, which can deteriorate into acute respiratory distress syndrome. The primary etiology may be attributed to cytokine storm, which is triggered by the excessive release of proinflammatory cytokines and subsequently leads to immune dysregulation. Considering that high levels of interleukin-6 (IL-6) have been detected in several highly pathogenic coronavirus-infected diseases, such as severe acute respiratory syndrome in 2002, the Middle East respiratory syndrome in 2012, and COVID-19, the IL-6 pathway has emerged as a key in the pathogenesis of this hyperinflammatory state. Thus, we review the history of cytokine storm and the process of targeting IL-6 signaling to elucidate the pivotal role played by tocilizumab in combating COVID-19.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study 地西他滨诱导 p53 突变的三阴性乳腺癌患者产生 IRF7 介导的免疫反应:一项临床和转化研究
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-29 DOI: 10.1007/s11684-023-1016-8

Abstract

p53 is mutated in half of cancer cases. However, no p53-targeting drugs have been approved. Here, we reposition decitabine for triple-negative breast cancer (TNBC), a subtype with frequent p53 mutations and extremely poor prognosis. In a retrospective study on tissue microarrays with 132 TNBC cases, DNMT1 overexpression was associated with p53 mutations (P = 0.037) and poor overall survival (OS) (P = 0.010). In a prospective DEciTabinE and Carboplatin in TNBC (DETECT) trial (NCT03295552), decitabine with carboplatin produced an objective response rate (ORR) of 42% in 12 patients with stage IV TNBC. Among the 9 trialed patients with available TP53 sequencing results, the 6 patients with p53 mutations had higher ORR (3/6 vs. 0/3) and better OS (16.0 vs. 4.0 months) than the patients with wild-type p53. In a mechanistic study, isogenic TNBC cell lines harboring DETECT-derived p53 mutations exhibited higher DNMT1 expression and decitabine sensitivity than the cell line with wild-type p53. In the DETECT trial, decitabine induced strong immune responses featuring the striking upregulation of the innate immune player IRF7 in the p53-mutated TNBC cell line (upregulation by 16-fold) and the most responsive patient with TNBC. Our integrative studies reveal the potential of repurposing decitabine for the treatment of p53-mutated TNBC and suggest IRF7 as a potential biomarker for decitabine-based treatments.

摘要 p53 在半数癌症病例中发生突变。然而,目前还没有针对 p53 的药物获得批准。在此,我们将地西他滨重新定位为三阴性乳腺癌(TNBC)的靶向药物,TNBC是一种p53突变频繁、预后极差的亚型乳腺癌。在一项针对 132 例 TNBC 病例的组织芯片回顾性研究中,DNMT1 过表达与 p53 突变(P = 0.037)和总生存期(OS)差(P = 0.010)相关。在一项DEciTabinE和卡铂治疗TNBC(DETECT)的前瞻性试验(NCT03295552)中,地西他滨联合卡铂治疗12例IV期TNBC患者的客观反应率(ORR)为42%。在9名有TP53测序结果的试验患者中,6名p53突变患者的ORR(3/6 vs. 0/3)和OS(16.0 vs. 4.0个月)均高于p53野生型患者。在一项机理研究中,与具有野生型 p53 的细胞系相比,携带 DETECT 衍生 p53 突变的同源 TNBC 细胞系表现出更高的 DNMT1 表达和地西他滨敏感性。在 DETECT 试验中,地西他滨诱导了强烈的免疫反应,在 p53 突变的 TNBC 细胞系(上调了 16 倍)和反应最强烈的 TNBC 患者中,先天性免疫因子 IRF7 的上调非常明显。我们的综合研究揭示了将地西他滨重新用于治疗 p53 突变的 TNBC 的潜力,并建议将 IRF7 作为地西他滨治疗的潜在生物标志物。
{"title":"Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study","authors":"","doi":"10.1007/s11684-023-1016-8","DOIUrl":"https://doi.org/10.1007/s11684-023-1016-8","url":null,"abstract":"<h3>Abstract</h3> <p>p53 is mutated in half of cancer cases. However, no p53-targeting drugs have been approved. Here, we reposition decitabine for triple-negative breast cancer (TNBC), a subtype with frequent p53 mutations and extremely poor prognosis. In a retrospective study on tissue microarrays with 132 TNBC cases, DNMT1 overexpression was associated with p53 mutations (<em>P</em> = 0.037) and poor overall survival (OS) (<em>P</em> = 0.010). In a prospective DEciTabinE and Carboplatin in TNBC (DETECT) trial (NCT03295552), decitabine with carboplatin produced an objective response rate (ORR) of 42% in 12 patients with stage IV TNBC. Among the 9 trialed patients with available <em>TP53</em> sequencing results, the 6 patients with p53 mutations had higher ORR (3/6 vs. 0/3) and better OS (16.0 vs. 4.0 months) than the patients with wild-type p53. In a mechanistic study, isogenic TNBC cell lines harboring DETECT-derived p53 mutations exhibited higher DNMT1 expression and decitabine sensitivity than the cell line with wild-type p53. In the DETECT trial, decitabine induced strong immune responses featuring the striking upregulation of the innate immune player <em>IRF7</em> in the p53-mutated TNBC cell line (upregulation by 16-fold) and the most responsive patient with TNBC. Our integrative studies reveal the potential of repurposing decitabine for the treatment of p53-mutated TNBC and suggest IRF7 as a potential biomarker for decitabine-based treatments.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139071809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovation-driven trend shaping COVID-19 vaccine development in China 中国 COVID-19 疫苗研发的创新驱动趋势
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-16 DOI: 10.1007/s11684-023-1034-6
Yuntao Zhang, Yuxiu Zhao, Hongyang Liang, Ying Xu, Chuge Zhou, Yuzhu Yao, Hui Wang, Xiaoming Yang

Confronted with the Coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized. Likewise, new technologies may provide more potent or broader immunity and will contribute to fight against hypermutated SARS-CoV-2 variants. All in all, with the ultimate aim of delivering robust and durable protection that is resilient to emerging infectious disease, alongside the traditional routes, the discovery of innovative approach to developing effective vaccines based on virus properties remains our top priority.

面对 2019 年冠状病毒病(COVID-19)大流行,中国已成为应对严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)传播和变异的重要力量,拥有多个创新平台,为这场持久战提供了多种技术手段。基于 SARS-CoV-2 尖峰蛋白或灭活全病毒的疫苗源自合作研究,是应对 COVID-19 的公共卫生措施的基石。在此,我们概述了多种途径的代表性疫苗,同时也总结了现有疫苗策略的优点和困境。同样,新技术可能会提供更强或更广泛的免疫力,并将有助于对抗高突变的 SARS-CoV-2 变种。总之,我们的最终目标是在传统途径的基础上,为新出现的传染病提供强大而持久的保护,因此,根据病毒特性探索开发有效疫苗的创新方法仍然是我们的首要任务。
{"title":"Innovation-driven trend shaping COVID-19 vaccine development in China","authors":"Yuntao Zhang, Yuxiu Zhao, Hongyang Liang, Ying Xu, Chuge Zhou, Yuzhu Yao, Hui Wang, Xiaoming Yang","doi":"10.1007/s11684-023-1034-6","DOIUrl":"https://doi.org/10.1007/s11684-023-1034-6","url":null,"abstract":"<p>Confronted with the Coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized. Likewise, new technologies may provide more potent or broader immunity and will contribute to fight against hypermutated SARS-CoV-2 variants. All in all, with the ultimate aim of delivering robust and durable protection that is resilient to emerging infectious disease, alongside the traditional routes, the discovery of innovative approach to developing effective vaccines based on virus properties remains our top priority.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138692020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GID complex regulates the differentiation of neural stem cells by destabilizing TET2. GID 复合物通过破坏 TET2 的稳定性来调节神经干细胞的分化。
IF 3.9 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2023-12-01 Epub Date: 2023-09-14 DOI: 10.1007/s11684-023-1007-9
Meiling Xia, Rui Yan, Wenjuan Wang, Meng Zhang, Zhigang Miao, Bo Wan, Xingshun Xu

Brain development requires a delicate balance between self-renewal and differentiation in neural stem cells (NSC), which rely on the precise regulation of gene expression. Ten-eleven translocation 2 (TET2) modulates gene expression by the hydroxymethylation of 5-methylcytosine in DNA as an important epigenetic factor and participates in the neuronal differentiation. Yet, the regulation of TET2 in the process of neuronal differentiation remains unknown. Here, the protein level of TET2 was reduced by the ubiquitin-proteasome pathway during NSC differentiation, in contrast to mRNA level. We identified that TET2 physically interacts with the core subunits of the glucose-induced degradation-deficient (GID) ubiquitin ligase complex, an evolutionarily conserved ubiquitin ligase complex and is ubiquitinated by itself. The protein levels of GID complex subunits increased reciprocally with TET2 level upon NSC differentiation. The silencing of the core subunits of the GID complex, including WDR26 and ARMC8, attenuated the ubiquitination and degradation of TET2, increased the global 5-hydroxymethylcytosine levels, and promoted the differentiation of the NSC. TET2 level increased in the brain of the Wdr26+/- mice. Our results illustrated that the GID complex negatively regulates TET2 protein stability, further modulates NSC differentiation, and represents a novel regulatory mechanism involved in brain development.

大脑发育需要神经干细胞(NSC)自我更新和分化之间的微妙平衡,而这依赖于基因表达的精确调控。十-十一转位 2(TET2)作为一种重要的表观遗传因子,通过对 DNA 中的 5-甲基胞嘧啶进行羟甲基化来调节基因表达,并参与神经元的分化。然而,TET2在神经元分化过程中的调控作用仍然未知。在这里,与 mRNA 水平相反,TET2 蛋白水平在 NSC 分化过程中通过泛素-蛋白酶体途径降低。我们发现 TET2 与葡萄糖诱导降解缺陷(GID)泛素连接酶复合物(一种进化保守的泛素连接酶复合物)的核心亚基有物理相互作用,并且自身也被泛素化。在NSC分化过程中,GID复合物亚基的蛋白水平与TET2水平呈对等增长。沉默GID复合体的核心亚基,包括WDR26和ARMC8,可减轻TET2的泛素化和降解,提高全局5-羟甲基胞嘧啶水平,促进NSC的分化。Wdr26+/-小鼠脑中的TET2水平升高。我们的研究结果表明,GID复合物能负向调节TET2蛋白的稳定性,进一步调节NSC的分化,是一种参与脑发育的新型调控机制。
{"title":"GID complex regulates the differentiation of neural stem cells by destabilizing TET2.","authors":"Meiling Xia, Rui Yan, Wenjuan Wang, Meng Zhang, Zhigang Miao, Bo Wan, Xingshun Xu","doi":"10.1007/s11684-023-1007-9","DOIUrl":"10.1007/s11684-023-1007-9","url":null,"abstract":"<p><p>Brain development requires a delicate balance between self-renewal and differentiation in neural stem cells (NSC), which rely on the precise regulation of gene expression. Ten-eleven translocation 2 (TET2) modulates gene expression by the hydroxymethylation of 5-methylcytosine in DNA as an important epigenetic factor and participates in the neuronal differentiation. Yet, the regulation of TET2 in the process of neuronal differentiation remains unknown. Here, the protein level of TET2 was reduced by the ubiquitin-proteasome pathway during NSC differentiation, in contrast to mRNA level. We identified that TET2 physically interacts with the core subunits of the glucose-induced degradation-deficient (GID) ubiquitin ligase complex, an evolutionarily conserved ubiquitin ligase complex and is ubiquitinated by itself. The protein levels of GID complex subunits increased reciprocally with TET2 level upon NSC differentiation. The silencing of the core subunits of the GID complex, including WDR26 and ARMC8, attenuated the ubiquitination and degradation of TET2, increased the global 5-hydroxymethylcytosine levels, and promoted the differentiation of the NSC. TET2 level increased in the brain of the Wdr26<sup>+/-</sup> mice. Our results illustrated that the GID complex negatively regulates TET2 protein stability, further modulates NSC differentiation, and represents a novel regulatory mechanism involved in brain development.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10234969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca2+ homeostasis in a murine model of HFpEF. 小檗碱通过调节 Drp1 介导的线粒体分裂和 Ca2+ 平衡,缓解小鼠高频心衰模型的心肌舒张功能障碍。
IF 8.1 3区 医学 Q1 Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-01 DOI: 10.1007/s11684-023-0983-0
Miyesaier Abudureyimu, Mingjie Yang, Xiang Wang, Xuanming Luo, Junbo Ge, Hu Peng, Yingmei Zhang, Jun Ren

Heart failure with preserved ejection fraction (HFpEF) displays normal or near-normal left ventricular ejection fraction, diastolic dysfunction, cardiac hypertrophy, and poor exercise capacity. Berberine, an isoquinoline alkaloid, possesses cardiovascular benefits. Adult male mice were assigned to chow or high-fat diet with L-NAME ("two-hit" model) for 15 weeks. Diastolic function was assessed using echocardiography and noninvasive Doppler technique. Myocardial morphology, mitochondrial ultrastructure, and cardiomyocyte mechanical properties were evaluated. Proteomics analysis, autophagic flux, and intracellular Ca2+ were also assessed in chow and HFpEF mice. The results show exercise intolerance and cardiac diastolic dysfunction in "two-hit"-induced HFpEF model, in which unfavorable geometric changes such as increased cell size, interstitial fibrosis, and mitochondrial swelling occurred in the myocardium. Diastolic dysfunction was indicated by the elevated E value, mitral E/A ratio, and E/e' ratio, decreased e' value and maximal velocity of re-lengthening (-dL/dt), and prolonged re-lengthening in HFpEF mice. The effects of these processes were alleviated by berberine. Moreover, berberine ameliorated autophagic flux, alleviated Drp1 mitochondrial localization, mitochondrial Ca2+ overload and fragmentation, and promoted intracellular Ca2+ reuptake into sarcoplasmic reticulum by regulating phospholamban and SERCA2a. Finally, berberine alleviated diastolic dysfunction in "two-hit" diet-induced HFpEF model possibly because of the promotion of autophagic flux, inhibition of mitochondrial fragmentation, and cytosolic Ca2+ overload.

射血分数保留型心力衰竭(HFpEF)表现为左心室射血分数正常或接近正常、舒张功能障碍、心脏肥大和运动能力差。小檗碱是一种异喹啉生物碱,对心血管有益。成年雄性小鼠被分配到饲料或添加 L-NAME 的高脂饮食("两击 "模型)中,为期 15 周。使用超声心动图和无创多普勒技术评估小鼠的舒张功能。对心肌形态、线粒体超微结构和心肌细胞机械特性进行了评估。此外,还评估了饲料小鼠和 HFpEF 小鼠的蛋白质组学分析、自噬通量和细胞内 Ca2+。结果表明,在 "两击 "诱导的HFpEF模型中,心肌细胞体积增大、间质纤维化和线粒体肿胀等不利的几何变化会导致运动不耐受和心脏舒张功能障碍。HFpEF小鼠的E值、二尖瓣E/A比值和E/e'比值升高,e'值和最大再延长速度(-dL/dt)降低,以及再延长时间延长,都表明其舒张功能障碍。小檗碱可减轻这些过程的影响。此外,小檗碱还能改善自噬通量,减轻 Drp1 线粒体定位、线粒体 Ca2+ 过载和碎裂,并通过调节磷脂酰班和 SERCA2a 促进细胞内 Ca2+ 重摄入肌浆网。最后,小檗碱减轻了 "两击 "饮食诱导的高频心衰模型的舒张功能障碍,这可能是由于小檗碱促进了自噬通量、抑制了线粒体破碎和细胞膜Ca2+超载。
{"title":"Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca<sup>2+</sup> homeostasis in a murine model of HFpEF.","authors":"Miyesaier Abudureyimu, Mingjie Yang, Xiang Wang, Xuanming Luo, Junbo Ge, Hu Peng, Yingmei Zhang, Jun Ren","doi":"10.1007/s11684-023-0983-0","DOIUrl":"10.1007/s11684-023-0983-0","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) displays normal or near-normal left ventricular ejection fraction, diastolic dysfunction, cardiac hypertrophy, and poor exercise capacity. Berberine, an isoquinoline alkaloid, possesses cardiovascular benefits. Adult male mice were assigned to chow or high-fat diet with L-NAME (\"two-hit\" model) for 15 weeks. Diastolic function was assessed using echocardiography and noninvasive Doppler technique. Myocardial morphology, mitochondrial ultrastructure, and cardiomyocyte mechanical properties were evaluated. Proteomics analysis, autophagic flux, and intracellular Ca<sup>2+</sup> were also assessed in chow and HFpEF mice. The results show exercise intolerance and cardiac diastolic dysfunction in \"two-hit\"-induced HFpEF model, in which unfavorable geometric changes such as increased cell size, interstitial fibrosis, and mitochondrial swelling occurred in the myocardium. Diastolic dysfunction was indicated by the elevated E value, mitral E/A ratio, and E/e' ratio, decreased e' value and maximal velocity of re-lengthening (-dL/dt), and prolonged re-lengthening in HFpEF mice. The effects of these processes were alleviated by berberine. Moreover, berberine ameliorated autophagic flux, alleviated Drp1 mitochondrial localization, mitochondrial Ca<sup>2+</sup> overload and fragmentation, and promoted intracellular Ca<sup>2+</sup> reuptake into sarcoplasmic reticulum by regulating phospholamban and SERCA2a. Finally, berberine alleviated diastolic dysfunction in \"two-hit\" diet-induced HFpEF model possibly because of the promotion of autophagic flux, inhibition of mitochondrial fragmentation, and cytosolic Ca<sup>2+</sup> overload.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers of Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1